Stephen O’Rahilly is Professor of Clinical Biochemistry and Medicine and the co-director of the Wellcome-MRC Institute of Metabolic Science (IMS) at the University of Cambridge, UK. He also directs the MRC Metabolic Diseases Unit and is Head of the University Department of Clinical Biochemistry, Scientific Director of the NIHR Biomedical Research Centre and a Fellow of Pembroke College.

He qualified from University College Dublin and completed his postgraduate training in London, Oxford and Boston before setting up his laboratory in Cambridge in 1991.

He is interested in the aetiology and pathophysiology of human metabolic and endocrine disease, and how such information might be used to improve the diagnosis, therapy and prevention of these diseases. One major area of continuing interest is to better understand why some people are susceptible to obesity and others seem resistant.

He was elected to the Royal Society in 2003, a Foreign Associate of the National Academy of Sciences USA in 2011 and was appointed a Knight Bachelor in 2013. His findings have been recognised internationally with multiple awards, including the Association of Physicians (AoP) highest award for an Outstanding Contribution to Translational Medicine in 2023.

Duality of interest: Professor Sir Stephen O’Rahilly has received research support / grants from MRC and Wellcome and speaker’s honorarium / fees from Royal Society Award and University of Chicago lectures. He has also received board member / panel payments from Astra Zeneca and Pfizer together with consultancy fees from Astra Zeneca, Pfizer, Third Rock Ventures and Novo Nordisk.

Date: Summer 2023